As KRAS mutation is also known to drive cancer cell invasion and metastasis, we next tested the invasive ability of the HCT116 cells that lack KRAS mutation (HKH2) or that are resistant to MEK inhibitor treatment (TRAMR) cells (Fig. 6A,B). This evidence concerns the gene MAP2K7 and cancer.